Renal effects of 26-week administration of olmesartan medoxomil/hydrochlorothiazide in rats

Journal of Toxicological Sciences

Volumn 29, Issue 1, 2004, Pages 37-46

  Ogata, Seiya ^a   Sharyo, Satoru ^a   Hinman, Donald J ^b   Manabe, Sunao ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Clinical Development   (United States)

Author keywords

Antihypertensive; Diuretic; Hydrochlorothiazide; Olmesartan medoxomil; Renoprotective effect; Urinary protein

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIURETIC AGENT; DRINKING WATER; HYDROCHLOROTHIAZIDE; OLMESARTAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CHRONIC PROGRESSIVE NEPHROPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; FEMALE; HEMODYNAMICS; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LOW DRUG DOSE; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN URINE LEVEL; RAT; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION; TOXICOKINETICS; TOXICOLOGICAL PARAMETERS; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALIA;

EID: 1642504392     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.29.37     Document Type: Article

References (23)

1. Bagdon, W.J., Bokelman, D.L., Stone, C.A. and Usui, T. (1985): Toxicity study of MK-421 (enalapril maleate) (II) - Subacute, chronic toxicity studies, saline supplementation, sodium-depletion in rats. J. Pharmacol. Ther., 13, 29-70.
2. Berg, B.N. (1965): Spontaneous nephrosis with proteinuria, hyperglobulinemia, and hypercholesterolemia in the rats. Proc. Soc. Exp. Biol. Med., 119, 417-420.
3. Bolton, W.K. and Sturgill, B.C. (1976): Spontaneous glomerular sclerosis in aging Sprague-Dawley rats. Am. J. Pathol., 98, 339-356.
4. Bucher, J.R., Huff, J., Haseman, J.K., Eustis, S.L., Elwell, M.R., Davis, W.E. Jr. and Meierhenry, E.F. (1990): Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 1. Hydrochlorothiazide. J. Appl. Toxicol., 10, 359-367.
5. Dunnett, C.W. (1955): A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc., 12, 1096-1121
6. Dunnett, C.W. (1964): New tables for multiple comparisons with a control. Biometrics, 20, 482-491
7. Gray, J.E. and Purmalis, A. (1965): Diet, proteinuria and kidney degeneration in the Sprague-Dawley (Upjohn) rats. Mich. State Univ. Vet., 25, 83-88.
8. Hashimoto, K., Imai, K., Yoshimura, S. and Ohtaki, T. (1981): Experimental toxicity study of an angiotensin I (ACE I) converting enzyme inhibitor, captopril - 3. Twelve month studies on the chronic toxicity of captopril in rats. J. Toxicol. Sci., 6 (Suppl. II), 215-246.
9. Hollenberg, N.K. (1983a): Renin, angiotensin, and the kidney: Assessment by pharmacologic interruption of the renin-angiotensin system. In The Kidney in Liver Disease (Epstein, M., ed.), 2nd ed., pp. 395-411, Elsivier Science Publishing, New York.
10. Hollenberg, N.K. (1983b): Pathophysiology of congestive heart failure: The role of the kidney. In Drug Treatment of Heart Failure. (Cohn, J.N., ed.), pp. 53-81, York Medical Books, New York.
11. Imai, K., Yoshimura, S., Ohtaki, T. and Hashimoto, K. (1981): Experimental toxicity study of an angiotensin I (ACE I) converting enzyme inhibitor captopril in the rats. J. Toxicol. Sci., 6 (Suppl. II), 189-214.
12. Jackson, E.K. (2001): Diurtetics. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman, A.G., ed.), 10th ed., pp. 757-787, McGraw-Hill, New York.
13. Kanno, Y., Okada, H., Suzuki, H., Ikenaga, H. and Saruta, T. (1994): Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats. Blood pressure, Suppl. 5, 67-70.
14. Koga, K., Yamagishi, S., Takeuchi, M., Inagaki, Y., Amano, S., Okamoto, T., Saga, T., Makita, Z. and Yoshizuka, M. (2002): CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol. Med., 8, 591-599.
15. Koike, H. (2001): New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol., 87 (suppl), 33C-36C.
16. Lijinsky, W. and Reuber, M.D. (1987): Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol. Ind. Health, 3, 413-422.
17. Mezzano, S.A., Ruiz-Ortega, M. and Egido, J. (2001): Angiotensin II and renal fibrosis. Hypertension, 38, 635-638.
18. Mizuno, M., Sada, T., Kato, M. and Koike, H. (2002): Renoprotective effects of blockage of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens. Res., 25, 271-278.
19. Narama, I., Nakajima, H., Fujishima, H., Kurio, W., Maeda, H., Ozaki, K., Kumagai, Y., Hiramatsu, Y. and Takabatake, E. (1993): Twelve-month oral toxicity study of tranpolapril (RU44570) in rats. J. Toxicol. Sci., 18 (Suppl. I), 37-92.
20. Navis, G., Faber, H.J., de Zeeuw, D. and de Jong, P.E. (1996): ACE inhibitors and the kidney. A risk-benefit assessment. Drug. Saf., 15, 200-211.
21. Short, B.G. and Goldstein, R.S. (1992): Nonneoplastic lesions in the kidney. In Pathology of the Aging Rats (Mohr, U., Dungworth, D.L. and Capen, C.C., eds.), Vol. 1, pp. 211-240, ILSI Press, Washington D.C.
22. Wolf, G. (1998): Molecular mechanisms of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics. Nephrol. Dial. Transplant., 13, 1131-1142.
23. Xu, H.L., Yoshida, K., Wu, X.M. and Kohzuki, M. (2001): Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats. Nippon Jinzo Gakkai Shi., 43, 580-588.